/manager/Index ${session.getAttribute("locale")} 5 Polymorphisms in nucleotide excision repair genes and susceptibility to colorectal cancer in the Polish population /manager/Repository/uon:27053 Wed 11 Apr 2018 16:37:42 AEST ]]> Inflammatory response gene polymorphisms and their relationship with colorectal cancer risk /manager/Repository/uon:4866 Wed 11 Apr 2018 16:25:23 AEST ]]> Serum concentrations of selenium and copper in patients diagnosed with pancreatic cancer /manager/Repository/uon:23842 Wed 11 Apr 2018 14:23:39 AEST ]]> Can selenium levels act as a marker of colorectal cancer risk? /manager/Repository/uon:14831 Wed 11 Apr 2018 13:24:36 AEST ]]> Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility /manager/Repository/uon:10390 Wed 11 Apr 2018 12:49:05 AEST ]]> Clinical characteristics of tumors derived from colorectal cancer patients who harbor the Tumor Necrosis Factor beta-1031T/T and NOD2 3020insC polymorphism /manager/Repository/uon:8123 Sat 24 Mar 2018 08:40:02 AEDT ]]> Prevalence of the E318K and V320I MITF germline mutations in Polish cancer patients and multiorgan cancer risk-a population-based study /manager/Repository/uon:20712 Sat 24 Mar 2018 08:06:21 AEDT ]]> Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer? /manager/Repository/uon:24833 A, del5395, I157T), NBS1 (657del5) and PALB2 (509-510delGA, 172-175delTTGT). A statistically significant association between the 657del5 mutation and an increased risk of pancreatic cancer was observed for NBS1 gene. The Slavic NBS1 gene mutation (657delACAAA) was detected in 8 of 383 (2.09%) unselected cases compared with 22 of 4,000 (0.55%) controls (OR: 3.80, p = 0.002). The PALB2 509_510delGA and 172-175delTTGT mutations combined were seen in 2 (0.52%) unselected cases of PaCa and in 8 (0.20%) of 4,000 controls (OR: 2.61, p = 0.49). For BRCA1, the three mutations combined were detected in 4 of 383 (1.04%) PaCa patients and in 17 of 4,000 (0.42%) controls (OR: 2.46, p = 0.20). CHEK2 mutations were not associated with the risk of pancreatic cancer (OR: 1.11, p = 0.72). The founder mutation in NBS1 (657del5) was associated with an increased risk of PaCa in heterozygous carriers, indicating that this mutation appears to predispose to cancer of the pancreas. By identifying pancreatic cancer risk groups, founder mutation testing in Poland should be considered for people at risk for PaCa.]]> Sat 24 Mar 2018 07:15:11 AEDT ]]>